Welcome to our dedicated page for Zoetis news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on Zoetis stock.
Zoetis Inc. (NYSE: ZTS) is described as the world’s leading animal health company, and the ZTS news feed on Stock Titan brings together company announcements, regulatory updates and product developments that shape its story. Zoetis focuses on medicines, vaccines, diagnostics and technologies for animals, serving veterinarians, pet owners and livestock producers in over 100 countries.
News items for Zoetis often highlight its research and development activities and regulatory milestones. Recent releases include Health Canada approval for Portela (relfovetmab injection) to alleviate pain associated with osteoarthritis in cats and European Commission marketing authorization for Lenivia (izenivetmab) to reduce osteoarthritis pain in dogs. These updates illustrate Zoetis’ emphasis on monoclonal antibody therapies and long-acting pain management solutions for companion animals.
Investors can also follow financial and capital markets news, such as announcements of convertible senior notes offerings, senior notes issuances and the use of proceeds for share repurchases and capped call transactions. The company regularly reports dividends declared by its board of directors and provides quarterly and annual financial results through press releases and Form 8-K filings.
Zoetis participates in major healthcare conferences and hosts webcasts, including innovation-focused events that discuss its pipeline across chronic kidney disease, oncology, cardiology, osteoarthritis pain and dermatology. These events, along with earnings calls and conference presentations, are frequently covered in the news stream.
By monitoring the ZTS news page, readers can review product approvals, R&D updates, capital allocation decisions, credit facility arrangements and governance developments reported by Zoetis. This page can be revisited to see how new therapies, financial actions and strategic communications are disclosed over time.
The Zoetis Foundation announced a commitment of $4.9 million to support 20 initiatives across Africa, Brazil, China, Ukraine, and the U.S. The funds will enhance veterinary scholarships, diversity programming, and mental wellness, while also aiding livestock farmers and relief efforts in Ukraine. An initial donation of $150,000 has been made to the Red Cross, with a matching commitment of up to $150,000 for colleague donations. The Foundation aims to improve livelihoods, education, and mental health support for veterinarians and farmers, backed by an overall $35 million commitment through 2025.
Zoetis Inc (NYSE:ZTS) will host a webcast and conference call on May 5, 2022, at 8:30 a.m. (ET) to discuss its first quarter 2022 financial results. CEO Kristin Peck and CFO Wetteny Joseph will lead the call. Investors can access the live webcast via the Zoetis investor website. Zoetis, the world's leading animal health company, generated $7.8 billion in revenue in 2021 and employs approximately 12,100 people globally. More details and a replay of the call will be available on the website.
Zoetis (NYSE:ZTS) will attend the Barclays Global Healthcare Conference on March 17, 2022, where Wetteny Joseph, Executive Vice President and CFO, will present at 9:30 a.m. ET. Interested investors can access a live audio webcast of the presentation at http://investor.zoetis.com/events-presentations. A replay will be available on the Zoetis website afterward. Zoetis, a leading animal health company, generated $7.8 billion in revenue in 2021 and operates in over 100 countries.
Summary not available.
Zoetis (NYSE:ZTS) will participate in the Bank of America Securities 2022 Animal Health Summit on February 24, 2022. Wetteny Joseph, CFO, will present at 2:30 p.m. ET, answering questions from analysts. The event will be accessible via a live audio webcast, available at investor.zoetis.com/events-presentations, with a replay provided afterwards. Zoetis is a leader in animal health, generating $7.8 billion in revenue in 2021, with innovations in medicines and diagnostics serving over 100 countries.
For Q4 2021, Zoetis reported $2.0 billion in revenue, marking a 9% increase year-over-year. Net income rose to $414 million or $0.87 per diluted share. For the full year, revenue reached $7.8 billion, a 16% growth, with net income at $2.0 billion or $4.27 per share. Zoetis anticipates 2022 revenues between $8.325 billion to $8.475 billion, projecting operational growth of 9% to 11%. The company achieved significant sales growth in its companion animal products, despite declines in livestock products due to competition and pricing pressures.
Zoetis Inc. (NYSE:ZTS) has announced a quarterly dividend of $0.325 per share, set for payment on June 1, 2022. This dividend will be distributed to all stockholders on record as of April 21, 2022. With a strong revenue of $6.7 billion in 2020, Zoetis stands as a leader in animal health, providing innovative solutions worldwide. This financial return reflects Zoetis's commitment to its shareholders and reinforces its robust market position.
Zoetis Inc. (NYSE:ZTS) announced FDA approval for Solensia™, the first injectable monoclonal antibody treatment for feline osteoarthritis (OA) pain. This once-monthly injection targets Nerve Growth Factor (NGF), effectively controlling OA pain and enhancing feline mobility and well-being. Studies show that 77% of cat owners observed improved pain signs in their cats after treatment. With nearly 40% of cats affected by OA, Solensia addresses a crucial need in veterinary care. It is anticipated to be available to veterinarians in the second half of 2022.
Zoetis (NYSE:ZTS) announced its commitment to achieving carbon neutrality in its operations by 2030. The initiative includes transitioning to 100% renewable energy, highlighted by a virtual power purchase agreement with Vesper Energy to supply 33% of its North American operational energy needs. Currently, 9 out of 28 manufacturing sites and several offices are already using 100% renewable electricity. Zoetis aims to enhance energy efficiency and transparency regarding emissions, reinforcing its sustainability leadership in animal health.
Zoetis (NYSE:ZTS) will participate in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022. CEO Kristin Peck is scheduled to present at 1:30 p.m. ET and will answer questions from analysts. Interested investors can access a live audio webcast of the presentation at http://investor.zoetis.com/events-presentations, with a replay available afterward. Zoetis is a leading animal health company with a revenue of $6.7 billion in 2020, supporting animal care globally.